VentureBeat

Posts Tagged ‘inv:Lotus-BioScience-Ventures’

KaloBios, a Palo Alto, Calif., biotech antibody-therapeutic company, raised $20 million in a third funding round. The company is developing new drugs based on monoclonal antibodies, which target specific cells or proteins in the body. Its lead candidate, an antibody against granulocyte macrophage colony-stimulating factor, or GM-CSF — a protein that helps regulate the white-blood-cell immune response — is intended to treat a variety of immune-related diseases such as rheumatoid arthritis and asthma.

Lehman Brothers led the round, joined by MPM Capital, Sofinnova Ventures, Alloy Ventures, 5AM Ventures, Singapore Bioinnovations, and Lotus BioScience Ventures. The funding will allow KaloBios to support clinical testing of two antibodies and to move a third into human tests.

Top Stories

Recent Comments

Powered by Disqus

Recent Guest Columnists

Job Board

Links

Venturebeat Writers

  • For advertising, contact .
  • Log in

Font Size

South San Francisco, Calif.-based KaloBios Pharmaceuticals, which develops non-human antibodies for use in human bodies, has taken $20 million in its fourth round of venture funding.
KaloBios is currently going through seven first- and second-phase clinical trials for two drugs and is working on a third, newer drug. The drugs are aimed at patients with cystic [...]

More ...